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Malignant cells are known to co-opt 
seemingly normal immune cells, such as 
tumor-associated macrophages (TAMs), 
to foster tumor growth and progression.1 
Large numbers of TAMs frequently accu-
mulate in the tumor stroma, and these 
cells can promote malignant progression 
by stimulating invasiveness, angiogenesis 
and metastasis as well as by suppressing 
antitumor immune responses. In addition, 
retrospective studies of patients affected by 
different types of cancer, including breast, 
bladder, ovarian, prostate and non-small 
cell lung carcinomas, indicate that ele-
vated TAM densities are associated with 
poor overall survival. Thus, TAMs consti-
tute candidate therapeutic targets for the 
treatment of various types of cancer.
Macrophages are terminally differenti-
ated cells that may not proliferate in the 
tumor stroma. Thus, as they turn over 
within a few days, TAMs must be con-
stantly replaced throughout cancer pro-
gression. In line with this notion, recent 
studies indicate that TAMs are continu-
ously replenished in vivo, mostly by circu-
lating inflammatory Ly-6Chi monocytes, 
which are cells that foster tumor progres-
sion.2,3 These findings suggest that tumors 
can act locally to promote the recruitment 
of immune cells that are normally present 
in the circulation.
Additional evidence indicates that 
some cancers alter the hematopoietic 
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system more profoundly, by remotely 
instigating the amplification of cells 
that promote tumor progression once 
recruited to the tumor microenviron-
ment. Indeed, the ontogenic analysis of 
TAMs in a murine model of lung adeno-
carcinoma (driven by the activation of 
oncogenic Kras coupled to the inactiva-
tion of p53, called KP) has revealed that 
cancer amplifies hematopoietic stem cells 
(HSCs) and instigates the expansion of 
macrophagic progenitors.3 This process 
predominantly occurs outside the bone 
marrow and within the splenic monocyte 
reservoir.4
Tumor-induced extramedullary 
progenitor activity seems to develop 
equally well in mice and humans, at 
least in individuals affected by inva-
sive tumors.3 Indeed, the splenocytes 
of patients manifesting pathological 
evidence of invasive cancer can con-
tain high amounts of lineage-negative 
CD117+CD34+CD38+IL3Ra+CD45RA+ 
cells, which resemble bone marrow 
myeloid progenitor cells. As expected, 
these cells are also PU.1+CEBPe+G-
C S F R + G M - C S F R + M P O + G ATA 1−
GATA3−vWF−IL7Ra− and differentiate 
into macrophages in vitro as well as when 
administered to immunodeficient mice 
bearing human lung adenocarcinoma 
xenografts.3 When taking quantitative 
differences between species into account, 
the magnitude of splenic macrophage 
progenitor amplification in mice and 
humans appears to be comparable.3 This 
amplification occurs in the absence of a 
notable expansion of splenic tissue, at least 
in KP mice. In contrast, mice engrafted 
with tumor cell lines often show enlarged 
spleens.
Adoptive transfer and splenectomy 
experiments have confirmed that a large 
fraction of TAMs can descend from splenic 
macrophage progenitors. Moreover, the 
accumulation of macrophage precursors in 
the spleen can promote tolerance toward 
tumor-associated antigens.5 These find-
ings suggest that (at least some) tumors 
have the ability to remotely interfere with 
the mononuclear phagocyte lineage in 
ways that favor tumor progression.
Identifying the factors whereby 
malignant cells remotely control tumor-
promoting macrophagic responses may 
provide novel targets for anticancer ther-
apy. Interestingly, tumor-bearing KP mice 
exhibit increased circulating levels of the 
peptide hormone angiotensin II (AngII).6 
In addition, the continuous delivery of 
AngII to otherwise healthy mice is suf-
ficient to phenocopy the tumor-induced 
splenic amplification of macrophage 
progenitors.6 The response mediated by 
AngII is independent of hemodynamic 
changes (blood pressure does not increase 
in tumor-bearing KP mice), selectively 
the communication between tumor and host cells involves signals that act across extended distances in the body. recent 
evidence indicates that the hormone angiotensin II is overproduced by lung adenocarcinoma to remotely expand bone 
marrow-derived hematopoietic stem cells. this process amplifies the supply of tumor-associated macrophages, which 
promote disease progression.
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requires the expression of the AngII recep-
tor AGTR1A on HSCs and downregulates 
the sphingosine-1-phosphate receptor 1 
(S1P1) signaling pathway in HSCs.6 This 
latter signal transduction cascade is essen-
tial for controlling the egression of HSCs 
from peripheral lymphoid tissues. Taken 
together, these data identify AngII as a 
prototypical signaling molecule that can 
be overproduced by cancer and act in an 
endocrine manner to actively stimulate 
the production of tumor-supporting cells 
(Fig. 1).
AngII signaling can be efficiently sup-
pressed by administering either angioten-
sin-converting enzyme inhibitors (ACEis) 
or AngII receptor blockers (ARBs). Both 
the ACEi enalapril and the ARB losartan 
restore S1P1 expression in the HSCs of 
tumor-bearing KP mice. Consequently, 
enalapril treatment prevents the ampli-
fication of both HSCs and macrophagic 
progenitors, restrains the TAM response 
and increases mouse survival (losartan has 
not been tested in this respect).6 The sur-
vival gain obtained with ACEi is equiva-
lent to that observed with standard-of-care 
chemotherapy.
Some retrospective clinical studies 
have begun to explore whether ACEis 
or ARBs may control cancer incidence 
and cancer-related death.7–9 Although 
these studies investigated cancer patients 
regardless of their AngII profile and TAM 
content, some of them suggest that ACEis 
or ARBs might reduce the incidence of 
specific malignancies such as lung and 
breast cancer. The putative antitumor 
effects of ACEis may depend on mecha-
nisms other than those controlling blood 
pressure, as the risk of developing a tumor 
apparently does not decrease in patients 
receiving other classes of antihypertensive 
drugs.7
At present, well-controlled prospec-
tive studies are needed to address whether 
ACEis or ARBs may be used to improve 
disease outcomes in selected cancer 
patient cohorts (e.g., patients exhibiting 
increased circulating levels of AngII). 
Increasing evidence suggests that TAMs 
modulate the efficacy of anticancer ther-
apy. Thus, controlling TAM production 
with agents such as ACEis may also be 
useful to design more effective combi-
nation therapies. Initial gene expression 
profiling studies suggest that angioten-
sinogen (the precursor of AngII) is fre-
quently overexpressed by tumor tissues, 
at least in lung and breast cancer patients 
(ref. 6 and unpublished data). However, 
only a subset of these patients might 
upregulate the AngII signaling path-
way.6 As hypertension may not necessar-
ily indicate increased circulating levels of 
AngII,10 patient selection may require a 
Figure 1. tumor remote control of hematopoietic stem cells and macrophagic progenitors through angiotensin II. In steady-state conditions, hemato-
poietic stem cells (hsCs) and macrophagic progenitors typically reside in bone marrow niches and generate (pro-)monocytes. A small number of hsCs 
constantly enter the circulation, extravasate at distant sites and migrate through peripheral tissues, including the spleen. under normal conditions, 
these cells can re-enter the blood and ultimately, return to their niches in the bone marrow. the process of cell recirculation is controlled at least in 
part by a chemotactic gradient of sphingosine-1-phosphate (s1P) that is established between peripheral tissues, lymphatics and the blood, where 
s1P concentration is the highest. thus, in steady-state conditions, only a few hsCs can be found in the spleen. Multiple types of cancer including lung 
adenocarcinomas produce angiotensin II (AngII), which directly signals through the AGtr1A receptor expressed on hsCs. this induces the downregu-
lation of the s1P receptor 1 (s1P1), hence reducing the ability of hsCs to sense the s1P gradient. In these conditions, hsCs accumulate in the spleen 
where they give rise to monocytes. By continuously producing monocytes, the spleen can contribute tAMs throughout tumor progression. thus, 
tumors can directly exploit the endocrine system to promote tumor progression. Drugs that interfere with the AngII pathway (or perhaps with s1P1 
signaling) may hence become therapeutic options for treating lung cancer patients in whom this pathway is elevated.
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direct quantification of AngII concentra-
tions in the blood.
The control operated by tumors on the 
host immune system extends well beyond 
the local microenvironment. Identifying 
tumor-derived long-range factors that are 
capable of amplifying tumor-supporting 
immune cells may pave the way for new 
targeted anticancer regimens. AngII is 
one of such factor. However, tumors most 
likely exert a remote control on hema-
topoietic cells through a wide array of 
mediators, the majority of which remain 
to be discovered.
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